title: First experience of the AML-Berlin-Frankfurt-Münster group in pediatric patients with standard-risk acute promyelocytic leukemia treated with arsenic trioxide and all-trans retinoid acid.
abstract: Recently, studies in adults with acute promyelocytic leukemia (APL) showed high cure rates in low-risk patients treated with all-trans retinoid acid (ATRA) and arsenic trioxide (ATO), while toxicities were significantly reduced compared to the standard treatment with ATRA and chemotherapy. Here we report about first experience with 11 pediatric patients with low-risk APL treated with ATRA and ATO. All patients stayed in molecular remission. All suffered from hyperleukocytosis. Two patients experienced reversible severe side effects. One suffered from osteonecroses at both femurs, seizures, as well as posterior reversible encephalopathy syndrome, the other patient had an abducens paresis.
authors.affiliation: Department of Pediatric Hematology/Oncology, Hannover Medical School, Children's Hospital, Hannover, Germany.
authors.forename: Ursula
authors.initials: U
authors.lastname: Creutzig
authors.affiliation: Department of Pediatrics, St. Anna Children's Hospital and Children's Cancer Research Institute, Medical University of Vienna, Vienna, Austria.
authors.forename: Michael N
authors.initials: MN
authors.lastname: Dworzak
authors.affiliation: Division for Pediatric Hematology and Oncology, Johann Wolfgang Goethe-University, Frankfurt, Germany.
authors.forename: Konrad
authors.initials: K
authors.lastname: Bochennek
authors.affiliation: Department of Pediatric Hematology/Oncology, University Medicine of the Johannes Gutenberg-University Mainz, Mainz, Germany.
authors.forename: Jörg
authors.initials: J
authors.lastname: Faber
authors.affiliation: Division of Pediatric Hematology/Oncology, University Medical Center, Freiburg, Germany.
authors.forename: Christian
authors.initials: C
authors.lastname: Flotho
authors.affiliation: Department of Pediatric Oncology/Hematology, Saarland University, Homburg, Germany.
authors.forename: Norbert
authors.initials: N
authors.lastname: Graf
authors.affiliation: Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Aachen, Germany.
authors.forename: Udo
authors.initials: U
authors.lastname: Kontny
authors.affiliation: Department of Pediatric Hematology and Oncology, University Children's Hospital Muenster, Muenster, Germany.
authors.forename: Claudia
authors.initials: C
authors.lastname: Rossig
authors.affiliation: Department of Pediatric Hematology and Oncology, Dr. von Hauner Children`s Hospital, Ludwig-Maximilians-University Munich, Munich, Germany.
authors.forename: Irene
authors.initials: I
authors.lastname: Schmid
authors.affiliation: Department of Pediatric Oncology/Hematology, Charité University Medical Center Berlin, Berlin, Germany.
authors.forename: Arend
authors.initials: A
authors.lastname: von Stackelberg
authors.affiliation: Department of Pediatric Hematology-Oncology, University of Duisburg-Essen, Essen, Germany.
authors.forename: Jans-Enno
authors.initials: JE
authors.lastname: Mueller
authors.affiliation: Department of Pediatric Hematology-Oncology, University of Duisburg-Essen, Essen, Germany.
authors.forename: Christine
authors.initials: C
authors.lastname: von Neuhoff
authors.affiliation: Department of Pediatric Hematology-Oncology, University of Duisburg-Essen, Essen, Germany.
authors.forename: Dirk
authors.initials: D
authors.lastname: Reinhardt
authors.affiliation: Department of Pediatric Hematology-Oncology, University of Duisburg-Essen, Essen, Germany.
authors.forename: Nils
authors.initials: N
authors.lastname: von Neuhoff
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000008:administration & dosage* / Q000009:adverse effects; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy*; D008297:Male; D010087:Oxides / Q000008:administration & dosage* / Q000009:adverse effects; D012189:Retrospective Studies; D016896:Treatment Outcome; D014212:Tretinoin / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D001152:Arsenicals; D010087:Oxides; D014212:Tretinoin; D000077237:Arsenic Trioxide
keywords: ATO; ATRA; acute promyelocytic leukemia; children